Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dibotermin alfa - Medtronic

Next Previous
X
Search
Drug Profile

Dibotermin alfa - Medtronic

Alternative Names: Amplify™ rhBMP-2 Matrix; Bone morphogenetic protein-2 - Pfizer/Astellas; InductOs; INFUSE Bone Graft; PF-5208771; rhBMP 2 - Pfizer/Astellas; rhBMP-2/CPM; YM 484

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Medtronic Europe; Medtronic Sofamor Danek; Pfizer
  • Class Calcium regulators; Proteins
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fracture; Intervertebral disc degeneration
  • Phase II Postmenopausal osteoporosis; Pseudoarthrosis
  • No development reported Bone disorders; Osteoarthritis
  • Discontinued Cancer

Most Recent Events

  • 09 Apr 2021 Dibotermin alfa is still in phase II trials for Pseudoarthrosis (In adolescent, In children) in USA (Implant) (NCT02718131)
  • 01 Jun 2020 Medtronic and University of Alabama at Birmingham terminates phase II trial in Pseudarthrosis (In adolescents, In adults) in USA (NCT02718131)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bone-disorders in Denmark (Implant, Controlled release)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top